Skip to content

Quality of Life 1y and 2 y After VV-ECMO for COVID-19

Quality of Life 1y and 2 y After VV-ECMO for COVID-19, Measured by the 36-item Short Form Health Survey

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05780255
Enrollment
28
Registered
2023-03-22
Start date
2021-04-20
Completion date
2024-02-01
Last updated
2024-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Acute Respiratory Distress Syndrome, Death, Extracorporeal Membrane Oxygenation Complication, Quality of Life

Keywords

ECMO, COVID-19, quality of life

Brief summary

This study aims to investigate the quality of life and the outcome after veno-venous extracoporeal membrane oxygenation (ECMO) support fir severe acute respiratory syndrome (ARDS) in COVID-19 patients.

Detailed description

The investigators follow our COVID-19 patients supported by ECMO, we make phone calls or real-life visits to pthe patients to score the quality of life, by using the SF-36. The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality , social functioning , role emotional , and mental health. The participants are contacted 3 months, 6months, 1year and 2 years after the ECMO support started for evaluation of the SF-36.

Interventions

DEVICEVV-ECMO

veno-venous extracorporeal membrane oxygenation

Sponsors

University Hospital, Ghent
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with PCR-confirmed COVID-19 infection AND * Acute Respiratory Distress Syndrome who require veno-venous ECMO therapy.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
in-hospital mortalitymortality during hospitalisation, up to two years
Quality of life 1y after ECMO insertion1 yearResult of SF-36 1 year after VV-ECMO insertion
Quality of life 2y after ECMO insertion2 yearsResult of SF-36 2 years after VV-ECMO insertion

Secondary

MeasureTime frameDescription
Lung complications requiring surgical treatmentFrom the start of VV-ECMO support until weaning of VV-ECMO, up to two yearsHemothorax or lung abcedation
LOS hospitalfrom the day of hospital admission until the day that the participant is transferred to home, up to two yearslength of stay at the hospital
LOS ICUfrom the day of intensive care unit admission until the day of transfer to the ward, up to two yearslength of stay at the intensive care unit
Duration of mechanical ventilation2 years
death after hospital dischargeafter discharge from the hospital upon 2 years afterall-cause death
Incidence of acute kidney injuryfrom the day of hospital admission until the day that the participant is transferred to home, up to two years

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026